Results 51 to 60 of about 10,221 (208)
Trials, 2021 Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen +23 more
doaj +1 more source
Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery –Who Is Referring Them?
Clinical Endocrinology, Volume 104, Issue 4, Page 352-361, April 2026.ABSTRACT Objective Patients living with pituitary neuroendocrine tumours (PitNETs) present with a spectrum of clinical manifestations and often follow a circuitous route to diagnosis, resulting in diagnostic delays. The objective of this study is to identify and report the various sources of referrals for patients who underwent pituitary resection for ...
Doua S. Ahmed +11 more
wiley +1 more source
Male, Female, Other: Transgender and the Impact in Primary Care [PDF]
, 2016 Transgender includes patients at various stages of their journey. It is important that providers care for transgender patients with a culturally sensitive approach, awareness, and competent skill. There are new terms to learn.
Markwick, Laura
core +2 more sources
SAGE Open Medical Case Reports, 2023 Hypogonadotropic hypogonadism is a common finding in patients who are diagnosed with a prolactinoma. It can be accompanied by the presence of other pituitary hormone deficits, including secondary adrenal insufficiency and central hypothyroidism.
Lakshmi P Menon, Dinesh Edem
doaj +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.Loss of INPP5A in PitNETs disrupts IP3 clearance and drives aberrant PI3K/Akt activation. PKA‐dependent phosphorylation stabilizes MBD2 via 14‐3‐3σ, sustaining transcriptional silencing of INPP5A. MBD2 inhibition sensitizes tumors to standard treatments and limits PitNET growth.
Qian Jiang +12 more
wiley +1 more source
The birth and rise of a craniopharyngioma: the radiological evolution of an incidental craniopharyngioma detected on serial MRI during medical treatment of a macroprolactinoma [PDF]
, 2016 This case demonstrates the rare coexistence of a prolactinoma with craniopharyngioma and documents its radiological growth. This case suggests that patients with pituitary neoplasms should be followed closely and although prolactinomas can often be ...
Losa, Marco +3 more
core +1 more source
Equine Veterinary Education, Volume 38, Issue 3, Page e170-e179, March 2026.Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess +5 more
wiley +1 more source
AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. [PDF]
, 2019 Background: Pituitary adenomas have a high disease burden due to tumor growth/ invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be ...
Cano González, David A. +2 more
core
An uncommon cause of osteoporosis
Journal of Family Medicine and Primary Care, 2018 Osteoporosis in the younger age group is an important cause of morbidity. Prolactinoma is an uncommon but reversible cause of osteoporosis. The main mechanisms of osteoporosis in prolactinoma are reduced osteoblast activity and hypogonadism. A high index
Rohit Barnabas +5 more
doaj +1 more source
Journal of Neuroendocrinology, Volume 38, Issue 3, March 2026.Abstract Nonfunctioning pituitary adenomas (NFPAs) are common intracranial tumors that, despite being histologically benign, can exhibit invasive growth, as well as postoperative tumor progression. Surgical resection is the primary treatment of choice; however, residual tumor tissue is frequently observed, with between 30% and 50% of these cases ...
Thomas Skoglund +5 more
wiley +1 more source